Skip to main content
Fig. 3 | Journal of Biomedical Science

Fig. 3

From: Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

Fig. 3

Therapeutic efficacy of mAb-S5 against SARS-CoV-2 (WA1, D614, and Alpha) infection in hamsters. A The experimental flow chart is shown. Groups of Syrian hamsters (n = 5–6, 11–12 weeks of age) were intranasally challenged with SARS-CoV-2 (WA1, 1 × 105 TCID50 per hamster). After 3 h of challenge, Syrian hamsters were divided into two groups and intraperitoneally administered 1 mg or 5 mg of mAb-S5. Body weights were recorded daily. Body weight changes (%) relative to the day of viral challenge are plotted (B). Infectious virus titers C and viral RNA copies D in the lung were evaluated at Day 3 after virus challenge. E Pathological analysis of lung lobes at Day 6 postchallenge using standard HE staining. Red arrows indicate immune cell infiltration. Blue arrows indicate extensive fibrin filling the alveolar space. Yellow arrows indicate pneumocyte hyperplasia. Scale bars represent 100 μm F) Pathological severity scores were evaluated according to the percentage of inflammatory area for each section from each animal using the following scoring system: 0, no pathological change; 1, affected area ≤ 10%; 2, affected area 10–30%; 3, affected area 30–50%; and 4, affected area ≥ 50%. Body weight changes (%) relative to the day of D614G G and Alpha variant I challenge are plotted. Infectious virus titers in the lung measured 3 days after D614G H and Alpha J challenge are shown. Statistical significance was determined using the Kruskal–Wallis test with Dunn’s multiple comparison test: *p < 0.05, **p < 0.01, and ***p < 0.001

Back to article page